Inhibitors of the hiv integrase enzyme

A compound of formula (I)

• wherein:
• R1 is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, or C1-C8 heteroalkyl, wherein said C1-C8 alkyl, C2-C8 alkenyl, or C1-C8 heteroalkyl groups may be optionally substituted with at least one substituent independently selected from:
• halo, —OR12a, —N(R12aR12b), CC(O)N(R12aR12b), —NR12aC(O)N(R12aR12b), —NR12aC(O)R12a, —NR12aC(NR12a)N(R12aR12b), —SR12a, —S(O)R12a, —S(O)2R12a, —S(O)2N(R12aR12b), C1-C8 alkyl, C8-C14 aryl, C3-C8 cycloalkyl, and C2-C9 heteroaryl, wherein said C1-C8 alkyl, C6-C14 aryl, C3-C8 cycloalkyl, and C2-C9 heteroaryl groups are optionally substituted with at least one substituent independently selected from halo, —C(R12aR12bR12c), —OH, and C1-C8 alkoxy;
• R2 is hydrogen or C1-C8 alkyl;
• R3 is hydrogen, C1-C8 alkyl, —(CR7R8)tNR9R10, —S(O)zNR9R10, —C(O)NR9R10, or C1-C8 heteroalkyl, wherein said C1-C8 heteroalkyl is optionally substituted with R11;
• Z is —(CR4R4)n—, —C(R4)═C(R4)—, —C(R4)═C(R4)—(CR4R4)n—, —(CR4R4)n—C(R4)═C(R4)—, or —(CR4R4)n—C(R4)═C(R4)—(CR4R4)n—;
• each R4 is independently selected from hydrogen, halo, C1-C8 heteroalkyl, C1-C8 alkyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl, wherein said C1-C8 alkyl, C3-C8 cycloalkyl, C6-C14 aryl, C2-C9 cycloheteroalkyl, and C2-C9 heteroaryl are optionally substituted with at least one R13;
• R5 is hydrogen, C1-C8 heteroalkyl, C6-C14 aryl, C2-C8 alkenyl, or C1-C8 alkyl, wherein said C1-C8 alkyl is optionally substituted with at least one C3-C8 cycloalkyl or C6-C14 aryl group;
• R6 is hydrogen;
• each R7 and R8, which may be the same or different, are independently selected from hydrogen and C1-C8 alkyl;
• R9 and R10, which may be the same or different, are independently selected from hydrogen, C3-C8 cycloalkyl, C2-C9 cycloheteroalkyl, and C1-C8 alkyl, wherein said C1-C6 alkyl may be optionally substituted by at least one C2-C9 cycloheteroalkyl, C2-C9 heteroaryl, halo, or C6-C14 aryl group, and wherein said C6-C14 aryl group may be optionally substituted by at least one C1-C8 alkyl or halo group;
• or
• R9 and R10, together with the nitrogen atom to which they are attached, form a C2-C9 cycloheteroalkyl or a C2-C9 heteroaryl group, each of which is optionally substituted with at least one R13 group;
• R11 is C3-C8 cycloalkyl, C1-C8 heteroalkyl, C2-C9 cycloheteroalkyl, C6-C14 aryl, or C2-C8 heteroaryl, each of which is optionally substituted with at least one substituent independently selected from C1-C8 alkyl, C6-C14 aryl, C2-C9 heteroaryl, —CF3, —COR12a, —CO2R12a, and —OR12a;
• each R12a, R12b, and R12c, which may be the same or different, is independently selected from hydrogen, C1-C8 alkyl, and oxo;
• or
• R12a and R12b, together with the nitrogen atom to which they are attached, may form a C2-C9 cycloheteroalkyl group;
• each R13 is independently selected from halo, C1-C8 alkyl, —(CR7R8)tOR7, —C(O)R12a, —S(O)2R7, —(CR7R8)zC(O)NR12aR12b, —NR12aR12b, and —CF3;
• t is an integer from 1 to 3;
• each n, which may be the same or different, is independently selected and is an integer from 1 to 4;
• and
• each z, which may be the same or different, is independently selected and is 0, 1, or 2;
• or a pharmaceutically acceptable salt or solvate thereof, with the proviso that R5 is not hydrogen when Z is —(CH2)—, R1 is 2,4-difluorobenzyl, and R2, R3, and R6 are hydrogen.